Softwr

Healthcare · head to head

PathAI vs Phreesia

PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite
Phreesia logo

Phreesia

Healthcare

Patient intake, registration and payments platform for medical practices

From
Free
Rated
-
Full reviewWebsite

The short version

  • Only Phreesia has a free tier, so it costs nothing to try first.
  • Each has a real cost: PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.; Phreesia no price is published: the vendor states pricing is customised to organisation size, workflows and products used, and is given only as a tailored quote
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which PathAI and Phreesia actually diverge.

Attributes where PathAI and Phreesia differ
AttributePathAIPhreesia
Starting priceOn requestFree
Pricing modelquotesubscription
Free tierNoYes

Identical on both: platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

Only in Phreesia

Nothing recorded that PathAI does not also cover.

What people use each for

The jobs each tool is most often brought in to do.

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Phreesia
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Phreesia
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Phreesia
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Phreesia

Phreesia

  • Digital patient intake and registration ahead of an appointmentnot PathAI
  • Collecting patient payments as part of the intake workflownot PathAI
  • Automating clinical screening questionnaires at check-innot PathAI

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Phreesia

  • No price is published: the vendor states pricing is customised to organisation size, workflows and products used, and is given only as a tailored quote
  • The current free access to the Intake platform is time limited and ends on 31 December 2026, with the rate that follows undisclosed
  • A buyer must book a demo before receiving any figure

Pricing, plan by plan

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Phreesia

Free

No published plan breakdown. See the Phreesia review.

Which should you pick?

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Choose Phreesia if

  • You want to start without paying.
Phreesia review

Questions people ask

Is PathAI or Phreesia better?
Neither clearly leads. PathAI starts at On request and Phreesia at Free, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, PathAI or Phreesia?
Phreesia has a free tier; the other does not. Paid plans start at On request for PathAI and Free for Phreesia.
Does PathAI or Phreesia run on more platforms?
Both run on Web, so platform support will not decide this one for you.
Can I use Phreesia for free?
Yes. Phreesia has a free tier, so you can try it without paying. PathAI starts at On request.
What is PathAI best used for?
PathAI is most often used for an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version, a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location, a pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readers, a laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewer. Of those, an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version and a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location are not what Phreesia is typically brought in for.
What can PathAI do that Phreesia cannot?
PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Phreesia: Is there a free version of Phreesia?

Phreesia offers free access to the complete Phreesia Intake platform through December 31, 2026. Standard subscription pricing begins January 1, 2027, with transparent pricing and no per-message charges or hidden fees.

Source
PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Phreesia: How is Phreesia priced?

Phreesia pricing is customized based on organization size, workflows, and products used. The company offers transparent subscription pricing with no per-message charges. Specific pricing requires contacting the company via their demo request form for a tailored quote.

Source
PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on PathAI

More on Phreesia

Keep looking

Other head to heads